Industry Newsfasn inhibitoracneascletisphase iii
Ascletis Announces Positive Phase III Results For Denifanstat
|
3.6
Ascletis reports positive topline Phase III open-label results for denifanstat (ASC40), a once-daily oral FASN inhibitor for acne. The company says denifanstat demonstrated favorable safety and tolerability in the study.
Scoring Rationale
Moderate novelty and segment impact; limited efficacy details and RSS-only source reduce confidence in broader significance.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
